Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

George Gavrila

Baltimore, MD Medical Doctor

NPI 1861627994 CMS profile 84293

29 S Paca St, Family Medicine, Lower Level, Baltimore, MD 21201

Open in the dashboard

General payments

$312,389

527 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, George Gavrila of Baltimore, MD is reported in the CMS Open Payments database as having received $312,389 across 527 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $15,414 60
2024 General $62,413 83
2023 General $49,660 73
2022 General $44,389 93
2021 General $24,273 52
2020 General $51,047 62
2019 General $65,194 104

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • George Gavrila
  • Maryland median
  • Middle half of Maryland
  • National median

In program year 2025, general payments to George Gavrila were reported at $15,414. Among 20,588 Maryland profiles paid that year, the median was $166 and the middle half received between $51 and $580.

Show as a table
Year George Gavrila Maryland median Middle half National median
2019 $65,194 $165 $50–$633 $163
2020 $51,047 $114 $37–$407 $114
2021 $24,273 $130 $36–$480 $132
2022 $44,389 $150 $45–$529 $149
2023 $49,660 $155 $47–$557 $160
2024 $62,413 $169 $53–$600 $164
2025 $15,414 $166 $51–$580 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $116,005 197 payments
  2. AbbVie, Inc. $110,344 110 payments
  3. Galderma Laboratories, L.P. $83,771 174 payments
  4. Revance Therapeutics, Inc. $2,084 45 payments
  5. Merz North America, Inc. $185 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $223,163 81 payments
  2. Consulting Fee $47,360 13 payments
  3. Travel and Lodging $30,702 55 payments
  4. Food and Beverage $11,144 376 payments
  5. Education $20 2 payments
Products named General payments · program years 2019–2025
  1. BOTOX $100,401 147 payments
  2. BOTOX COSMETIC $53,279 89 payments
  3. DAXXIFY $2,084 45 payments
  4. KYBELLA $1,950 1 payment
  5. DYSPORT $221 10 payments
  6. DYSPORT $112 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

527 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record